Laëtitia Moinot

Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial

Andrew J. Pollard, Odile Launay, Jean‐Daniel Lelièvre et al. · The Lancet Infectious Diseases · 2020 · 170 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +14

Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 Inter-ACTIV): a randomised controlled phase 3 clinical trial

P. Mercié, Julie Arsandaux, Christine Katlama et al. · The Lancet HIV · 2018 · 66 citations

Public Health, Pharmacology, Pharmacotherapy +10

Safety and immunogenicity of the live attenuated intranasal pertussis vaccine BPZE1: a phase 1b, double-blind, randomised, placebo-controlled dose-escalation study

Maja Jahnmatz, Laura Richert, Nabil Al‐Tawil et al. · The Lancet Infectious Diseases · 2020 · 56 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +16

Week 96 efficacy of lopinavir/ritonavir monotherapy in virologically suppressed patients with HIV: a randomized non-inferiority trial (ANRS 140 DREAM)

Jean‐Luc Meynard, Laëtitia Moinot, Roland Landman et al. · Journal of Antimicrobial Chemotherapy · 2018 · 11 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17